Summary ACNU [1-(4-amino-2-methyl-5-pyrimidinyl) Meningeal gliomatosis (MG), characterised either by its pathologically multifocal nature or its diffuse infiltration of glioma cells into the subarachnoid space, is a serious complication of malignant glioma and has been thought to be comparatively rare (Yung et al., 1980) . However, it has been disclosed that the incidence of MG is 10-20% of patients with malignant brain tumours, and recent reports have claimed its increase along with the prolongation of life span of patients with malignant glioma (Arita et al., 1984; Yoshida et al., 1986a,c). Furthermore, the prognosis of these patients has not been significantly modified to date.
Meningeal gliomatosis (MG), characterised either by its pathologically multifocal nature or its diffuse infiltration of glioma cells into the subarachnoid space, is a serious complication of malignant glioma and has been thought to be comparatively rare (Yung et al., 1980) . However, it has been disclosed that the incidence of MG is 10-20% of patients with malignant brain tumours, and recent reports have claimed its increase along with the prolongation of life span of patients with malignant glioma (Arita et al., 1984; Yoshida et al., 1986a,c) . Furthermore, the prognosis of these patients has not been significantly modified to date.
Systemic chemotherapy cannot achieve an effective drug concentration in cerebrospinal fluid (CSF) to overcome the drug resistance acquired during the initial chemotherapy for the primary tumour (Levin et al., 1985 (Levin et al., , 1989 Yoshida et al., 1984b Yoshida et al., , 1985 Yoshida et al., , 1986b Yoshida et al., , 1987a . Thus, the treatment of MG is limited to radiation therapy of the brain and the spinal cord and/or the use of a limited number of antitumour drugs which can be administered directly into the spinal subarachnoid space (intrathecally) or cerebral ventricles (Bleyer, 1978; Hitchins et al., 1987) . Although radiotherapy is sometimes effective, as in CNS leukaemia prophylaxis, it has toxic effects on the brain that result in intellectual impairment even at low doses (Hutsu et al., 1973) . Drugs such as methotrexate (Blasberg et al., 1977; Schulier et al., 1985; Shapiro et al., 1977) , 1-P-D-arabinofuranosylcytosine (Edwards et al., 1981; Fulton et al., 1982) , thio-TEPA (Gutin et al., 1976 (Gutin et al., , 1977 , bleomycin (Levin et al., 1985; Ushio et al., 1987) , and neocarzinostatin (Matsukado et al., 1980; Yoshida et al., 1987b) intrathecally administered have demonstrated some therapeutic effect, however, the results are not sufficient (Ushio et al., 1987) .
One of the chloroethylnitrosoureas (CENUs), ACNU [1- (4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride] (Nakamura et al., 1977) , has been used via intravenous administration and has demonstrated remarkable efficacy as the other CENUs against brain tumours diffusely invading into the parenchyma (Takakura et al., 1986) . However, the systemic administration of this drug is not always effective on MG (Ushio et al., 1987; Yoshida et al., 1984a (Levin et al., 1985) . Accordingly, these characteristics are considered to be favourable for intrathecal chemotherapy with respect to the side effects of the chemotherapeutic agents (Ohashi, 1987 (Arita et al., 1988; Yoshida et al., 1984a Yoshida et al., ,b,c, 1987c . Antitumour activity was expressed as follows: the mean survival time of the ACNUtreated group divided by the mean survival time of the control group (T/C).
In vitro sensitivity assay A colony-forming assay (Deen et al., 1979) Pathological examination MG rats without treatment were sacrificed for histological examination on Day 5. The intact skull and vertebral column were freed from overlying soft tissue, fixed in 10% formalin, then decalcified. The brains were cut coronally and embedded in parafin. Coronal sections of the brain of 5 ji in thickness were processed for the hematoxylin-eosin (HE) and immunoperoxidase method using antiserum to glial fibrillary acidic protein (GFAP) (Bignami et al., 1972) . This immuno histological method has been described (Yoshimine et al., 1982) . Briefly, the indirect peroxidase-labelled method was carried out at room temperature. Figure 1 . In the control groups and the groups of rats which received 0.5, 1.0 or 1.5 mg kg-1 of intrathecal ACU treatment, the body weight of the rats constantly increased and neither loss of appetite, behavioural changes nor neurological signs were observed during or after intrathecal administration. On the other hand, in the group treated with 3.0 mgkg-1 ACNU, the body weight of the rats rapidly decreased to approximately 70% of baseline, and 60% of the rats died of acute toxicity of ACNU showing acute appetite loss, and various kinds of neurological signs or behavioural changes such as a decrease in activity, nervous reactions, a tendency toward violence, hemiparesis, muscular spasms and respiratory disorders.
In the rats given over 3.0 mg kg-' of intrathecal ACNU, the subpial regions of the ambient cistern, the base of the brain and the hippocampal fissue were stained with Evans blue 5 days after injection. Pathologically, neuronal loss and gliosis were also noted in the same regions as above. These changes were observed thereafter up to 30 days after injection. In the rats intrathecally administered with ACNU at dosages less than 1.5 mg kg-', neither the extravasation of Evans blue nor pathological changes such as those mentioned above were observed up to 30 days after injection. Table I demonstrates the results of intrathecal chemotherapy with ACNU in MG rats at dosages of 0.5, 1.0, or 1.5 mg kg-'. When intrathecally administered 1 day or 3 days after tumour inoculation, ACNU markedly prolonged the survival time of MG rats (Figures 2 and 3a,b) . When the animals were treated with 1.5 mg kg-1 of ACNU on Day 1, the T/C value was 163.4% and 265.0% for C6 MG and 9L MG rats, respectively, and on Day 3, it was 140.9% and 190.1% for C6 MG and 9L MG rats, respectively. Intrathecal ACNU administered 5 days after tumour inoculation failed to prevent tumour growth in C6 MG rats, but not in 9L MG rats in which the median survival time (MST) was still prolonged by the treatment with 1.0 or 1.5 mg kg-' ACNU, and the T/C value was 125.0% and 135.0%, respectively (Figures 2 and 3c, Table I ). Table II demonstrates the results after intravenous treatment of MG rats with ACNU at a dosage of 15 mg kg-'. In C6 MG rats, no chemotherapeutic effect was observed in any of the regimens, while the MST of 9L MG rats was significantly prolonged by an intravenous administration of ACNU. When treated 1, 3, or 5 days after tumour inoculation, intravenous ACNU prolonged the survival time of 9L MG rats, by the T/C values, 157.0%, 171.0% and 187.0%, respectively. Intrathecal treatment with a one-tenth dose of ACNU displayed more efficacy than did intravenous treatment 1 day after tumour inoculation, whereas the latter was more effective than the former 5 days after tumour inoculation.
Effect of intrathecal ACNU in MG rats
Drug sensitivity of C6 and 9L cells in vitro The dose response curves for C6 and 9L cells are shown in Figure 4 . C6 cells were more resistant to ACNU than were 9L cells in vitro.
Pathologicalfindings
The pathological changes in the rats intracisternally inoculated with C6 glioma cells 5 days after tumour inoculation are shown in Figure 5 . The immunoperoxidase method demonstrated an intense astrocytic reaction in the vicinity of the tumour invasion. The reaction was manifested as the proliferation of hypertrophied astrocytes, which developed fibrillated processes. Furthermore, a direct tumour invasion by destroying the ependymal cell barrier was observed in the lateral, third and fourth ventricles at this stage. The ependymal cells reacted strongly with the GFAP antiserum. 
Discussion
The treatment of meningeal gliomatosis (MG) is limited to irradiation to the brain and the spinal cord or to the use of a limited number of drugs that can be intrathecally or intraventricullarly administered (Levin et al., 1989) . These conventional treatments have failed to lead to satisfactory results in treating patients with MG. It has been reported that the incidence of this disorder is relatively high and that it is increasing along with recent progress in the treatment of brain tumours (Arita et al., 1988; Ushio et al., 1987; Yoshida et al., 1986a Yoshida et al., ,c, 1987c . Due to the limited information available concerning the pathophysiology of this disease, no consistent method of treatment has yet been introduced. Therefore, it is necessary to design a more effective therapy for this disease. While examining the alternative methods of treatment for MG, we have observed the efficacy of the intrathecal administration of ACNU in rat animal models (Yoshida et al., 1984b) . Although the feasibility of this therapy has been extensively studied (Arita et al., 1988; Nagatani et al., 1986; Kochi et al., 1990; Levin et al., 1989; Yoshida et al., 1987c) , further studies with regard to the pathophysiology of MG and the drug sensitivity of the tumour cells are required in order to investigate the most appropriate regimen of this new therapy. Pharmacokinetics and pharmacodynamics of A CNU in vivo According to the results of a toxicity test, a dose of up to 1.5 mg kg-' of ACNU was proven t9 be safely administered intrathecally. The antitumour activity of intrathecal ACNU at dosages of 0.5, 1.0 and 1.5 mg kg-' was examined in MG models. It was shown that the median survival time of MG rats was statistically prolonged with low dosages of the drug (0.5 or 1 mg kg-') in the early stages of MG (1 or 3 days after tumour inoculation), however a comparatively high dose of ACNU (1.5 mg kg-') failed to demonstrate its satisfactory efficacy in the late stages of MG (later than 5 days after tumour inoculation). By contrast, intravenous therapy with 15 mg kg-' of ACNU displayed more efficacy in the late stages of 9L MG rats than did intrathecal therapy although no chemotherapeutic effects was seen in C6 MG rats.
According to Rosenblum et al. (Rosenblum et al., 1983) , the maximum clinically achievable dose of the chemotherapeutic agents at the tumour cell in situ was estimated to be 8.5 JLM when a single intravenous dose of BCNU was administered at a clinical dose of 180 to 220 mg sq m-. Furthermore, they reported that the cell kill value of 40% in vitro can be logically adopted to estimate a clinical response to chemotherapy in vivo. In the present study, 40% cell kill value in vitro required 2.3 JAM of ACNU for 9L cells and 21.4 JLM for C6 glioma cells, respectively. This explains the results of the present experiments in which intravenous ACNU did not demonstrate any therapeutic effect in C6 MG rats, while it did in 9L MG rat models. This suggests that the achievable dose of ACNU in vivo by intravenous administration is insufficient in some tumour cells originally resistant to ACNU, such as C6 glioma cells, in attaining the cell kill to bring about a clinical response. On the other hand, high CSF concentrations and the AUC (area under the drug concentration-time curve) values were obtained when ACNU was perfused through the intraventricular administration in the dogs (Kochi et al., 1990) , and intraventricular or intrathecal bolus administration of BCNU also achieved the high values of the maximum concentration and AUC in human trials (Levin et al., 1989) . Although these data can support the results of the remarkable therapeutic effect of intrathecal therapy for both C6 and 9L MG models in the early stages of MG, the diminished effect of intrathecal ACNU therapy in the late stages cannot be explained.
Pathophysiology of MG and blood-brain barrier (B.B.B.) In order to clarify the above mentioned phenomenon, the pathophysiology must be understood. According to our previous study on MG (Yoshida et al., 1986a,c) , tumour cells inoculated into the subarachnoid space remained to be floating cells in the CSF with forming spheroids a few days after tumour inoculation. On the third day, the tumour began to invade the parenchyma through the perivascular space of the penetrating vessels, which was followed by the complete invasion into the parenchyma by the 5th day after tumour inoculation ( Figure 5 ). This might be one of the reasons for the reduced effect of ACNU accompanied by the progress of MG. Thus, once tumour cells start to invade into the parenchyma, it might become difficult to prevent tumour growth by intrathecal chemotherapy alone. Furthermore, the tumour nodules, along with the parenchymal invasion, were also observed in the late stages of MG rats. It has been demonstrated that the penetration of drugs into the tumour nodules greater than 5Smm was severely compromised in nodules of the peritoneal space tumour implants (Flessner et al., 1984 (Flessner et al., , 1985 (Yoshida et al., 1984b; 1986b,d; 1987a,b; Yoshida et al., 1987d) . Although CENUs are comparatively effective against glioma (Ushio et al., 1987) , the required drug concentration is relatively high in order to attain the effective cell kill in most of the clinical cases (Rosenblum et al., 1983) . For instance, using the data from Figure 4 , 1-log cell kill values for C6 and 9L cells become 91.0 and 9.6 liM, respectively. This means that C6 cells are originally ten times more resistant to ACNU than are 9L cells, which is the responsible factor for the failure of intravenous therapy for C6 MG rats. The other problem is how to treat patients with MG in its late stages. In spite of a remarkable therapeutic effect of a low dose of intrathecal ACNU in the early stages of MG, its efficacy decreased in the late stages of MG as the pathophysiology acutely altered in a short time. In these stages, tumour cells have already deeply invaded the parenchyma, to which ACNU cannot easily reach by an intrathecal administration. Indeed, Arita et al. demonstrated that intracisternally administered ACNU quickly spread in the subarachnoid space and subpial layer of the brain and that the drug could not penetrate into the parenchyma (Arita et al., 1988) . Therefore, it is stressed that the treatment of MG should be carried out depending on its pathophysiological and clinical stages, which was partly reported in our previous communications (Yoshida et al., 1986a,c; 1987c) . The additional treatments, including combination chemotherapy (Yoshida et al., 1984a; 1987a) , are necessary for the advanced stages of MG. Further studies are under way to gain better understanding of these particular problems in the treatment of MG.
